Go to the list of all blogs
published in Blogs
Apr 23, 2026

Northrop Grumman (NOC): Unpacking the -14% Drop Over the Past 30 Days

Key Takeaways

  • NOC stock declined -14% over the past 30 days, driven by a post-earnings selloff despite beating Q1 estimates, amid broader defense sector weakness.
  • Over the past quarter, shares fell -12% after peaking mid-period, reflecting initial gains from strong backlog growth followed by market rotation out of defensives.
  • Key drivers include in-line full-year guidance, supply chain concerns, and investor worries over potential peak defense spending.
  • A robust $96 billion backlog and 5% organic sales growth in Q1 highlight resilient demand, supporting long-term fundamentals.
  • Analyst consensus remains bullish with price targets above current levels, signaling potential rebound opportunities.

Northrop Grumman (NOC): Company Overview and Market Position

Northrop Grumman Corporation (NOC) stands as a leading global aerospace and defense technology company. It operates through four main segments: Aeronautics Systems, Space Systems, Mission Systems, and Defense Systems. The company designs, develops, and produces advanced aircraft, spacecraft, missile systems, and cyber solutions for government and commercial clients, primarily the U.S. Department of Defense (DoD).

In my view, NOC's business model, built on long-term government contracts, research and development (R&D), and a massive backlog that provides revenue visibility, gives it a strong edge. As a top-tier defense contractor alongside peers like Lockheed Martin, it holds a competitive position in strategic programs such as the B-21 Raider bomber and next-generation missile defense. These fundamentals explain recent stock behavior: steady contract wins buoyed shares earlier, but sector headwinds have pressured prices amid volatile market trends.

NOC Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, NOC stock dropped -14%, closing at $589.62 on April 22 from around $682 on March 24. The decline was volatile, with shares peaking near $747 mid-March before a sharp pullback, range-bound in early April, and accelerating lower post-earnings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

For the past quarter, the stock fell -12%, from approximately $671 on January 23 to the current $590 level. Performance featured an initial uptrend to all-time highs, followed by trend-driven selling, reflecting heightened volatility in the aerospace and defense sector.

Key Drivers Behind NOC's 30-Day Price Decline

The primary catalyst for NOC's 30-day decline was the market's reaction to Q1 2026 earnings released April 21. The company reported revenue of $9.88 billion, surpassing estimates by 1.2%, and adjusted EPS (earnings per share) of $6.14, beating consensus by $0.06. Organic sales grew 5%, fueled by production ramps in aeronautics and space.

However, shares sold off over 7% the next day and continued lower, as full-year guidance of $43.5-44.0 billion matched Wall Street expectations without an upward revision. Supply chain disruptions and margin pressures cited in the report added caution. Broader defense sector sentiment shifted negative, with stocks labeled less "defensive" amid rising interest rates and rotation to growth names. Analyst notes highlighted oversold conditions, but short-term price movement reflected profit-taking from recent highs.

What Drove NOC Stock Over the Past Quarter

NOC shares rose over 11% early in the quarter, driven by a $96 billion backlog—up significantly year-over-year—and contract awards in missile defense and space systems. Geopolitical tensions boosted demand for Northrop's capabilities in long-range strike and cyber defense.

One thing that stands out is how the subsequent downturn stemmed from macroeconomic factors, including fears of peaking U.S. defense budgets despite elevated FY27 projections, and sector-wide rotation as investors favored cyclical industrials. Institutional selling increased amid high valuations post-rally, with the stock falling below its 50-day moving average. Cumulative impact favored fundamentals like backlog growth, but sentiment and sector trends dominated, leading to net -12% quarterly price movement.

Trending AI Robots: A Tool I Rely On

In my research and trading, I often turn to Tickeron’s Trending AI Robots page, which showcases the platform's top-performing artificial intelligence-driven trading bots from a library of hundreds that trade thousands of tickers across various markets. This curated section highlights only the most relevant and high-performing robots based on recent metrics like win rate, profit factor, and consistency—especially useful for stocks like NOC. Bots employ diverse strategies—ranging from momentum and mean reversion to neural network predictions—across timeframes from intraday to long-term swings. Performance data is transparently displayed, allowing users to filter by ticker relevance and risk-adjusted returns. Whether for stock analysis or automated trading, these tools adapt to market trends and have helped me refine my approach.

NOC Stock Outlook: Key Factors to Watch

From what I see, investors should monitor upcoming Q2 earnings for updates on backlog conversion, margins, and supply chain progress. Key industry trends include DoD budget deliberations for FY27, potential increases in missile defense spending, and advancements in programs like the B-21 Raider. I'm watching this closely.

The macro environment—interest rates, inflation, and geopolitical risks—could influence sector flows. Strategic developments such as new contracts or partnerships in space and cyber will be critical. Risks include budget sequestration threats or execution delays, while catalysts like analyst upgrades or peer outperformance may shift sentiment. Track volume and moving averages for technical signals in stock price analysis. This is important because it underscores the balance between near-term pressures and long-term strengths.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: NOC

NOC in upward trend: price may jump up because it broke its lower Bollinger Band on September 30, 2026

NOC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 38 cases where NOC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 71%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where NOC advanced for three days, in 206 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NOC as a result. In 40 of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.

The Moving Average Convergence Divergence Histogram (MACD) for NOC turned negative on September 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 26 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 58%.

NOC moved below its 50-day moving average on August 31, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NOC crossed bearishly below the 50-day moving average on September 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 61%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NOC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.

The Aroon Indicator for NOC entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 36 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.018) is normal, around the industry mean (6.305). P/E Ratio (16.078) is within average values for comparable stocks, (58.116). Projected Growth (PEG Ratio) (3.350) is also within normal values, averaging (2.564). Dividend Yield (0.019) settles around the average of (0.009) among similar stocks. P/S Ratio (1.766) is also within normal values, averaging (18.330).

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. NOC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NOC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 38.94B. The market cap for tickers in the group ranges from 4.49 to 1.92T. SPCX holds the highest valuation in this group at 1.92T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was -1%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -11%. SPCX experienced the highest price growth at 18%, while PUSA experienced the biggest fall at -21%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 45
P/E Growth Rating: 70
Price Growth Rating: 62
SMR Rating: 77
Profit Risk Rating: 76
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
NOC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of innovative systems, products and solutions in aerospace, electronics and information systems

Industry AerospaceDefense

Industry
Aerospace And Defense
Address
2980 Fairview Park Drive
Phone
+1 703 280-2900
Employees
95000
Web
https://www.northropgrumman.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.